Dr. Shore on extended follow-up data for darolutamide in nonmetastatic CRPC

Urology Times staff

Neal D. Shore, MD, medical director of the Carolina Urologic Research Center, discusses extended follow-up data from the phase 3 ARAMIS trial of darolutamide (Nubeqa) in nonmetastatic castration-resistant prostate cancer that were shared during the 2021 ASCO Annual Meeting. The FDA approved the androgen receptor pathway inhibitor in July 2019 for the treatment of patients with nonmetastatic castration-resistant prostate cancer, based on findings from the phase 3 ARAMIS trial.